News Sentiment

BLRX sentiment intelligence

BioLineRx Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.90 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

77/100 classification confidence.

Company focus 34

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-6.1% over one week, -8.2% over four weeks, trend active, and below fair value.

Latest direct headline Positive

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 77/100 classification
One-week reaction -6.1% Price reacting lower
Trend fit Trend active -8.2% over four weeks
Fair value -86.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 22
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 34
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
PR Newswire 9
Market source 6
TradingView 6
Stock Titan 5
Moomoo 3
Quartr 2
dars.gov.et 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 16
Guidance 3
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 43
Stock Titan Direct company coverage

Preclinical Ovarian Cancer Data Show GLIX1-PARP Synergy

BioLineRx and Hemispherian announced that preclinical data demonstrating a strong synergy between GLIX1, a TET2-activating small molecule, and PARP inhibitors in HR-proficient ovarian cancer will be presented as an e-Poster at ESMO 2026. This is significant because HR-proficient

Tone
Positive 66/100
Event
Market update
Published
20 Jul 2026 11:10
Source
Stock Titan
Quartr Direct company coverage

BioLineRx (BLRX) Q4 2024 earnings summary

BioLineRx (BLRX) reported a significant strategic shift in Q4 2024, focusing on lean drug development in oncology and rare diseases by shutting down U.S. commercial operations and reducing annual cash burn by over 70%. The company entered an exclusive licensing agreement for moti

Tone
Positive 66/100
Event
Balance sheet
Published
17 Jul 2026 15:13
Source
Quartr
Quartr Direct company coverage

BioLineRx (BLRX) Q4 2025 earnings summary

BioLineRx (BLRX) reported its Q4 2025 earnings, highlighting a decrease in revenue to $1.2 million, down from $28.9 million in 2024, primarily due to APHEXDA royalties. The company successfully advanced GLIX1 into clinical development for glioblastoma, resolved a legal dispute, a

Tone
Positive 67/100
Event
Earnings
Published
16 Jul 2026 19:40
Source
Quartr
TradingView Direct company coverage

Enterprise value to revenue forward of BioLineRX Ltd. – TASE:BLRX

This article presents the enterprise value to revenue forward for BioLineRX Ltd. (TASE:BLRX). It shows the period, value, and change for this financial metric. The content highlights the stock's listing on the Tel Aviv Stock Exchange and provides a general overview of financials.

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 15:13
Source
TradingView
TradingView Direct company coverage

Price to book forward of BioLineRX Ltd. – TASE:BLRX

This article presents the "Price to book forward" financial metric for BioLineRX Ltd. (TASE:BLRX). It shows the value of this metric over different periods and notes that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 10:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of BioLineRX Ltd. – TASE:BLRX

This article provides the enterprise value to EBITDA forward for BioLineRX Ltd. (TASE:BLRX) as presented on TradingView. The content is primarily a data point within a financial platform, focusing on a specific financial metric for the pharmaceutical company.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 07:11
Source
TradingView
grafa.com Direct company coverage

BioLineRx, Hemispherian post synergy in ovarian cancer model

BioLineRx and Hemispherian announced strong preclinical data showing therapeutic synergy between their oncology candidate GLIX1 and the PARP inhibitor olaparib in an ovarian cancer model. The low-dose combination achieved tumor reduction comparable to standard chemotherapy withou

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 15:39
Source
grafa.com
Stock Titan Direct company coverage

BioLineRx (NASDAQ: BLRX) reports GLIX1-PARP synergy in ovarian cancer model

BioLineRx and Hemispherian announced new preclinical data demonstrating strong synergistic effects between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer xenograft model. This combination showed significantly better efficacy than current treatments and

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 12:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

BioLineRx reports preclinical data on GLIX1 with PARP inhibitor By Investing.com

BioLineRx and Hemispherian AS announced positive preclinical data for GLIX1 combined with the PARP inhibitor olaparib in an ovarian cancer model, showing better efficacy than monotherapy even at lower doses. This combination achieved tumor reduction similar to cisplatin in homolo

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 11:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

BioLineRx’s ovarian cancer data shows GLIX1 can boost PARP drugs

BioLineRx and Hemispherian announced new preclinical data showing a strong synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The low-dose combination achieved similar tumor reduction to cisplatin, a chemotherapy benchmark,

Tone
Negative 39/100
Event
Market update
Published
08 Jul 2026 11:11
Source
Stock Titan
TradingView Direct company coverage

BLRX Forecast — Price Target — Prediction for 2027

This article provides a brief forecast for BioLineRx Ltd. (BLRX) for 2027, including an average price target of $17.50 based on analysis from two unnamed analysts. It also mentions that no maximum or minimum estimates were provided by these analysts. The forecast includes section

Tone
Positive 59/100
Event
Guidance
Published
27 Jun 2026 02:10
Source
TradingView
TradingView Direct company coverage

BioLineRX Ltd. Actuals & Estimates (TASE:BLRX)

This article provides financial actuals and estimates for BioLineRX Ltd. (TASE: BLRX), including its current stock price, historical performance, analyst forecasts, and upcoming earnings report. It advises against considering the information as investment advice and encourages re

Tone
Negative 38/100
Event
Earnings
Published
26 Jun 2026 13:10
Source
TradingView
The Globe and Mail Direct company coverage

BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze

BioLineRx's Q1 earnings call revealed significant scientific advancement in its glioblastoma pipeline with the GLIX1 trial commencement and increasing royalty income from APHEXDA. However, these positives were overshadowed by a swing to a net loss, a sharp decline in nonoperating

Tone
Negative 41/100
Event
Earnings
Published
12 Jun 2026 16:11
Source
The Globe and Mail
Moomoo Direct company coverage

Earnings Preview: BioLine Rx to Report Financial Results on May 27

BioLine Rx (BLRX.US) is scheduled to release its financial results on May 27 ET. Analysts estimate the company to post revenue of USD 343.00K and an EPS of USD-1.04 for Q1 2026. Companies typically hold a conference call around the publication date to discuss financial results an

Tone
Neutral 50/100
Event
Earnings
Published
06 Jun 2026 23:10
Source
Moomoo
MSN Direct company coverage

BioLineRx shares advance after first patient enrolled in GLIX1 cancer study (BLRX)

BioLineRx (BLRX) shares increased after the company announced the enrollment of the first patient in its randomized, controlled Phase 1/2 clinical study for GLIX1. The study is evaluating GLIX1 in adult patients with relapsed/refractory acute myeloid leukemia (AML), a particularl

Tone
Positive 87/100
Event
Market update
Published
02 Jun 2026 14:09
Source
MSN
Intellectia AI Direct company coverage

BioLineRx (BLRX) Q1 2026 Earnings Transcript

BioLineRx (BLRX) recently announced its Q1 2026 earnings, reporting a GAAP EPS of $0.00, significantly surpassing market expectations by $1.04, and revenue of $0.48 million, an 84.6% year-over-year increase. The company also initiated a Phase 1/2a clinical trial for GLIX1 in glio

Tone
Positive 73/100
Event
Earnings
Published
01 Jun 2026 11:39
Source
Intellectia AI
Zacks Small Cap Research Direct company coverage

BLRX: First Quarter 2026 Results

BioLineRx Ltd. (BLRX) reported first-quarter 2026 results, showing license revenues of $477,000 and a net loss of $2.6 million. The company's joint venture, Tetragon Biosciences, has begun a Phase I/IIa study for GLIX1 in glioblastoma and other cancers, with the first patient alr

Tone
Positive 63/100
Event
Earnings
Published
29 May 2026 07:10
Source
Zacks Small Cap Research